LFLee A. Fleisher

Lee A. Fleisher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lee A. Fleisher has a total of 478 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Improvement in Motor Status Among Regular Users of a Home-Based Brain-Computer Interface After Stroke

    by Phillip Demarest, Steven C. Cramer, Gregory E. Wilding, Nancey Trevanian Tsai, Sarah Gibbons, Nikhita J. Perry, Lee A. Fleisher, Eric C. Leuthardt, Seth J. Wilk

    Background: Upper extremity impairment persists in many stroke survivors, and few treatments are effective for severe chronic deficits. Brain-computer interface (BCI) therapy, which pairs decoded motor-intention-associated electrophysiology with sensory feedback, has improved upper extremity impairment in randomized trials, including in patients with severe paresis. Whether these benefits translate to routine care has rarely been evaluated. This study examined upper extremity motor recovery through 1 year among patients prescribed at-home BCI therapy in clinical practice. Methods: This retrospective observational study included adults who were prescribed the IpsiHand System, an electroencephalography-based BCI, through a commercial US home therapy program, had a baseline Upper Extremity Fugl-Meyer (UEFM) assessment, and averaged >1 session per week through their last assessment. Occupational therapists administered the UEFM by video every 4 weeks. The primary outcome was UEFM change from baseline to week 12. A mixed model for repeated measures estimated change through week 52, with multiple imputation sensitivity analyses for missing data. Results: Of 452 patients included in analyses (mean time since stroke, 5.4±5.4 years), mean baseline UEFM was 20.1±14.6, with 333 patients (73.7%) having severe motor impairment (UEFM 0-28). At week 12, mean UEFM change was 4.3 points (95% CI, 3.7–4.9; P<0.001), and 31.7% achieved the minimal clinically important difference (MCID) of 5.25 points. Mean change reached the MCID at week 16 (5.6, 95% CI [4.8, 6.4]). Model-estimated change in UEFM continued to improve through 1 year, being 6.1 (95% CI, 5.5–6.8) at week 24 and 8.1 (95% CI, 6.8–9.4) at week 52. Conclusions: Among regular users of at-home BCI therapy in routine care, most of whom had severe chronic impairment, UEFM scores improved by 12 weeks, reached MCID by 16 weeks, and continued to increase through 1 year. At-home BCI therapy merits evaluation in randomized trials with follow-up beyond 12 weeks.

  • Open Access

    Advancing Antimicrobial Stewardship With Diagnostic Excellence: The Role of Bayesian Reasoning

    by Ephraim L Tsalik, Neha K Prasad, Lee A Fleisher

    Antimicrobial resistance and inappropriate antibiotic use are urgent threats to global health and patient safety. Early antibiotic prescribing often occurs despite uncertain infection status, leading to unnecessary exposure and contributing to resistance. This article advocates for strengthening antimicrobial stewardship by integrating diagnostic stewardship and Bayesian reasoning to more explicitly consider disease probability in clinical decisions. In particular, probability thresholds should be included in clinical guidelines to inform testing decisions that may prompt antibiotic initiation. We provide several clinical examples and highlight the need for clinician education in Bayesian reasoning, underpinned by real-time decision support tools. Anchoring clinical practice in probability-based frameworks promises to refine antibiotic prescribing, enhance patient safety outcomes, and curb the progression of antimicrobial resistance.

  • Regional Anesthesia

    by Lee A. Fleisher

  • Open Access

    Towards responsible artificial intelligence in healthcare—getting real about real-world data and evidence

    by Eileen Koski, Amar Das, Pei-Yun Sabrina Hsueh, Anthony Solomonides, Amanda L Joseph, Gyana Srivastava, Carl Erwin Johnson, Joseph Kannry, Bilikis Oladimeji, Amy Price, et al.

    Background: The use of real-world data (RWD) in artificial intelligence (AI) applications for healthcare offers unique opportunities but also poses complex challenges related to interpretability, transparency, safety, efficacy, bias, equity, privacy, ethics, accountability, and stakeholder engagement. Methods: A multi-stakeholder expert panel comprising healthcare professionals, AI developers, policymakers, and other stakeholders was assembled. Their task was to identify critical issues and formulate consensus recommendations, focusing on the responsible use of RWD in healthcare AI. The panel’s work involved an in-person conference and workshop and extensive deliberations over several months. Results: The panel’s findings revealed several critical challenges, including the necessity for data literacy and documentation, the identification and mitigation of bias, privacy and ethics considerations, and the absence of an accountability structure for stakeholder management. To address these, the panel proposed a series of recommendations, such as the adoption of metadata standards for RWD sources, the development of transparency frameworks and instructional labels likened to “nutrition labels” for AI applications, the provision of cross-disciplinary training materials, the implementation of bias detection and mitigation strategies, and the establishment of ongoing monitoring and update processes. Conclusion: Guidelines and resources focused on the responsible use of RWD in healthcare AI are essential for developing safe, effective, equitable, and trustworthy applications. The proposed recommendations provide a foundation for a comprehensive framework addressing the entire lifecycle of healthcare AI, emphasizing the importance of documentation, training, transparency, accountability, and multi-stakeholder engagement.


  • Top Cited Papers
    Open Access

    Toward a responsible future: recommendations for AI-enabled clinical decision support

    by Steven Labkoff, Bilikis Oladimeji, Joseph Kannry, Anthony Solomonides, Russell Leftwich, Eileen Koski, Amanda L Joseph, Monica Lopez-Gonzalez, Lee A Fleisher, Kimberly Nolen, et al.

    Background: Integrating artificial intelligence (AI) in healthcare settings has the potential to benefit clinical decision-making. Addressing challenges such as ensuring trustworthiness, mitigating bias, and maintaining safety is paramount. The lack of established methodologies for pre- and post-deployment evaluation of AI tools regarding crucial attributes such as transparency, performance monitoring, and adverse event reporting makes this situation challenging. Objectives: This paper aims to make practical suggestions for creating methods, rules, and guidelines to ensure that the development, testing, supervision, and use of AI in clinical decision support (CDS) systems are done well and safely for patients. Materials and Methods: In May 2023, the Division of Clinical Informatics at Beth Israel Deaconess Medical Center and the American Medical Informatics Association co-sponsored a working group on AI in healthcare. In August 2023, there were 4 webinars on AI topics and a 2-day workshop in September 2023 for consensus-building. The event included over 200 industry stakeholders, including clinicians, software developers, academics, ethicists, attorneys, government policy experts, scientists, and patients. The goal was to identify challenges associated with the trusted use of AI-enabled CDS in medical practice. Key issues were identified, and solutions were proposed through qualitative analysis and a 4-month iterative consensus process. Results: Our work culminated in several key recommendations: (1) building safe and trustworthy systems; (2) developing validation, verification, and certification processes for AI-CDS systems; (3) providing a means of safety monitoring and reporting at the national level; and (4) ensuring that appropriate documentation and end-user training are provided. Discussion: AI-enabled Clinical Decision Support (AI-CDS) systems promise to revolutionize healthcare decision-making, necessitating a comprehensive framework for their development, implementation, and regulation that emphasizes trustworthiness, transparency, and safety. This framework encompasses various aspects including model training, explainability, validation, certification, monitoring, and continuous evaluation, while also addressing challenges such as data privacy, fairness, and the need for regulatory oversight to ensure responsible integration of AI into clinical workflow. Conclusions: Achieving responsible AI-CDS systems requires a collective effort from many healthcare stakeholders. This involves implementing robust safety, monitoring, and transparency measures while fostering innovation. Future steps include testing and piloting proposed trust mechanisms, such as safety reporting protocols, and establishing best practice guidelines.


  • Open Access

    Shaping Medicare’s Health Care Regulations

    by Sheila C. Blackstock, Adam C. Richards, Lee A. Fleisher

    Explore the latest in national and global health policy, including health care pricing, delivery, access, quality, safety, equity, and reform.


  • Monitoring: Back to the Future

    by Lee A. Fleisher